Although the pharma industry’s dealmaking activity in the last 12 months has yet to surpass the peak levels seen in previous years like 2019 when total deal values reached $264bn, mergers and acquisitions (M&As) saw somewhat of a resurgence in 2023. While there was a rebound in M&A deals from 2022 to 2023 in terms of total deal values was observed, M&A activity in Q1 2024 has dropped in comparison to Q1 2023 in terms of deal values. Oncology as a therapeutic area has consistently attracted the most deals over the years, with 2023’s highest-value deal also being in the cancer arena. At the same time, there was growing interest for M&As neurology and immunology last year.
Read the full article: Pharma M&A: The Top High Value Deals in 2023 //
Source: https://www.pharmaceutical-technology.com/features/pharma-ma-the-top-high-value-deals-in-2023/